Larotrectinib

ArtNr	HY-12866-5mg
Hersteller	MedChem Express
CAS-Nr.	1223403-58-4
Menge	5 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Kategorie	Metabolism Diabetes Glucose Homeostasis Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	99.95
Citations	[1]Karyn Bouhana, et al. LOXO-101, a pan TRK inhibitor, For The Treatment Of TRK-driven Cancers.\|[2]Nagasubramanian R, et al. Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101. Pediatr Blood Cancer. 2016 Aug;63(8):1468-70.\|[3]Kathryn G, et al. Genetic Modeling and Therapeutic Targeting of ETV6-NTRK3 with Loxo-101in Acute Lymphoblastic Leukemia. Blood 2016 128:278.\|[4]Doebele RC, et al. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Cancer Discov. 2015 Oct;5(10):1049-57. bioRxiv. 04 Nov 2021.\|bioRxiv. 2024 Feb 1.\|BMC Cancer. 2024 Dec 5;24(1):1502.\|Cell Rep Med. 2023 Jan 10;100911.\|Eur J Med Chem. 2020 Aug 30;207:112744.\|J Anal Sci Technol. 2020 Jun.\|Life. 2025 Jan 15;15(1):99.\|Mol Cancer Ther. 2021 Oct 8;molcanther.MCT-21-0632-A.2021.\|Mol Oncol. 2022 Oct 1.\|Ruprecht Karls University. The Faculty of Bio Sciences. 2023 Feb 2.\|Spectrochim Acta A Mol Biomol Spectrosc. 2023 Nov 5, 300, 122914.\|Nat Nanotechnol. 2025 Feb;20(2):311-324.
Smiles	O=C(N1C[C@@H](O)CC1)NC2=C3N=C(N4[C@@H](C5=CC(F)=CC=C5F)CCC4)C=CN3N=C2
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	LOXO-101,ARRY-470
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; Trk Receptor
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	428.44
Product Description	Larotrectinib (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).
Manufacturer - Research Area	Cancer
Solubility	DMSO: ≥ 4.6 mg/mL
Manufacturer - Pathway	Apoptosis; Neuronal Signaling; Protein Tyrosine Kinase/RTK
Isoform	TrkA; TrkB; TrkC
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-12866-5mg-safety-datasheet.pdf